March 30, 2021 09:51 AM EDT
Pharma
FDA+

HHS reg­u­la­to­ry agen­da for 2021 is light on new pro­posed and fi­nal FDA rules

Zachary Brennan

Senior Editor

The im­pact of the coro­n­avirus on the FDA’s work plans is ev­i­dent in the lat­est se­mi-an­nu­al reg­u­la­to­ry agen­da for HHS, which in­cludes on­ly two new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times